Aditxt Inc - ADTX STOCK NEWS

Aditxt, Inc. (NASDAQ: ADTX) announces a 1-for-40 reverse stock split effective on August 18, 2023.

Aditxt, a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, has signed a non-binding Letter of Intent to acquire Natural State Laboratories and Natural State Genomics. The acquisition would support revenue growth and provide Pearsanta with an expanded management team. The consideration for the transaction is not to exceed $55 million.

Aditxt's subsidiary Adimune has signed a clinical trial agreement with Mayo Clinic to advance clinical studies targeting autoimmune diseases of the central nervous system (CNS), starting with Stiff Person Syndrome (SPS). The collaboration aims to restore immune tolerance in patients with progressive autoimmune CNS disorders. The clinical trial is expected to begin in 2023 with enrollment of approximately 10-15 patients.

Aditxt, Inc. (NASDAQ: ADTX) has successfully closed a registered direct offering with a healthcare-focused institutional investor, selling 1,585,350 shares of common stock at $1.22 per share. The gross proceeds from this transaction amount to approximately $1.9 million, excluding fees and expenses. In addition, the company issued warrants for 3,170,700 shares at an exercise price of $0.86, valid for three years. The proceeds will be utilized for working capital and other corporate purposes. The offering was conducted under an effective shelf registration statement and complies with SEC regulations.

Aditxt is focused on technologies to monitor and modulate the immune system, with an emphasis on developing treatments for organ rejection, autoimmunity, and infectious diseases.

Aditxt, Inc. (NASDAQ: ADTX) has announced a definitive agreement with a healthcare-focused institutional investor to sell 1,585,350 shares of common stock at $1.22 each in a registered direct offering. Additionally, unregistered warrants to purchase 3,170,700 shares at an exercise price of $0.86 will be issued. The offering is expected to close around April 24, 2023, pending customary closing conditions. Gross proceeds are projected at $1.9 million, intended for working capital and corporate purposes. H.C. Wainwright & Co. serves as the exclusive placement agent.

Aditxt, Inc. (NASDAQ: ADTX) has signed an asset purchase agreement with Cellvera, granting Aditxt a 50% stake in Global Response Aid (GRA), a partnership with Agility. The deal involves a total transaction value of $24.5 million, which includes the forgiveness of a $14.5 million loan and $10 million in cash, alongside future royalties over seven years. This strategic acquisition aims to expand Aditxt’s capabilities in developing effective antiviral therapies, particularly focusing on the drug Avigan, which is licensed for use in multiple markets excluding Japan, China, and Russia. The agreement is contingent upon various approvals, including board and regulatory consents. Aditxt's CEO emphasizes that this acquisition is pivotal for driving future growth and addressing the rising demand for antiviral solutions.

Aditxt, Inc. (NASDAQ: ADTX) provides updates on its innovation programs and M&A strategies. Its subsidiary, Pearsanta, was designated as the backup bidder for the assets of Lucira Health Inc., which include FDA-approved COVID-19 and flu tests. Aditxt raised concerns during the auction about the asset sale's fairness. Additionally, Aditxt formed Adivir, Inc. to target the antiviral market, with ongoing discussions to acquire assets from Cellvera. Meanwhile, Adimune is progressing with human clinical trials in Germany, focusing on psoriasis, and aims to add trials in the U.S. by Q4 2023. The company reported having approximately $2.8 million in cash as of December 31, 2022, highlighting potential financing challenges ahead.

Aditxt (NASDAQ: ADTX) has appointed Maureen Connolly as its Chief Content and Engagement Officer. Connolly brings over 25 years of experience in health and technology, previously serving as Editor in Chief at Everyday Health. Her role will focus on enhancing stakeholder engagement and communication strategies. Amro Albanna, the CEO, emphasized her fit for the role, expecting her to drive the company’s mission. Aditxt is known for its advancements in immune system technologies, offering personalized immune profiles and developing preclinical modulating technologies aimed at addressing autoimmune diseases and organ transplant rejections.

Aditxt, Inc. (NASDAQ: ADTX) has partnered with Riverside Management Group to enhance the growth and revenue strategies for its subsidiary, Pearsanta, Inc.. This collaboration aims to identify strategic M&A opportunities to scale AditxtScore™, a platform that profiles the immune system. The Company recognizes Pearsanta's potential in precision medicine and plans to improve operational efficiency through automation. Aditxt's initiatives position it for significant financial milestones in 2023, with a strong focus on the healthcare sector.